These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 32108749)

  • 1. Nlrp3 Inflammasome Inhibitor MCC950 Ameliorates Obliterative Bronchiolitis by Inhibiting Th1/Th17 Response and Promoting Treg Response After Orthotopic Tracheal Transplantation in Mice.
    Xu KY; Tong S; Wu CY; Ding XC; Chen JL; Ming Y; Wang SH
    Transplantation; 2020 Jun; 104(6):e151-e163. PubMed ID: 32108749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of NLRP3 inflammasome by MCC950 improves the metabolic outcome of islet transplantation by suppressing IL-1β and islet cellular death.
    Matsuoka T; Yoshimatsu G; Sakata N; Kawakami R; Tanaka T; Yamada T; Yoshida Y; Hasegawa S; Kodama S
    Sci Rep; 2020 Oct; 10(1):17920. PubMed ID: 33087823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The selective NLRP3-inflammasome inhibitor MCC950 reduces myocardial fibrosis and improves cardiac remodeling in a mouse model of myocardial infarction.
    Gao R; Shi H; Chang S; Gao Y; Li X; Lv C; Yang H; Xiang H; Yang J; Xu L; Tang Y
    Int Immunopharmacol; 2019 Sep; 74():105575. PubMed ID: 31299609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The selective NLRP3 inflammasome inhibitor MCC950 alleviates cholestatic liver injury and fibrosis in mice.
    Qu J; Yuan Z; Wang G; Wang X; Li K
    Int Immunopharmacol; 2019 May; 70():147-155. PubMed ID: 30802677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective NLRP3 inflammasome inhibitor reduces neuroinflammation and improves long-term neurological outcomes in a murine model of traumatic brain injury.
    Xu X; Yin D; Ren H; Gao W; Li F; Sun D; Wu Y; Zhou S; Lyu L; Yang M; Xiong J; Han L; Jiang R; Zhang J
    Neurobiol Dis; 2018 Sep; 117():15-27. PubMed ID: 29859317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Pharmacology of the NLRP3 Inflammasome Inhibitor CP-456,773 (CRID3) in Murine Models of Dermal and Pulmonary Inflammation.
    Primiano MJ; Lefker BA; Bowman MR; Bree AG; Hubeau C; Bonin PD; Mangan M; Dower K; Monks BG; Cushing L; Wang S; Guzova J; Jiao A; Lin LL; Latz E; Hepworth D; Hall JP
    J Immunol; 2016 Sep; 197(6):2421-33. PubMed ID: 27521339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice.
    Mridha AR; Wree A; Robertson AAB; Yeh MM; Johnson CD; Van Rooyen DM; Haczeyni F; Teoh NC; Savard C; Ioannou GN; Masters SL; Schroder K; Cooper MA; Feldstein AE; Farrell GC
    J Hepatol; 2017 May; 66(5):1037-1046. PubMed ID: 28167322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NLRP3 Inflammasome Inhibition by MCC950 Reduces Atherosclerotic Lesion Development in Apolipoprotein E-Deficient Mice-Brief Report.
    van der Heijden T; Kritikou E; Venema W; van Duijn J; van Santbrink PJ; Slütter B; Foks AC; Bot I; Kuiper J
    Arterioscler Thromb Vasc Biol; 2017 Aug; 37(8):1457-1461. PubMed ID: 28596375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ameliorative effect of selective NLRP3 inflammasome inhibitor MCC950 in an ovalbumin-induced allergic rhinitis murine model.
    Zhang W; Ba G; Tang R; Li M; Lin H
    Int Immunopharmacol; 2020 Jun; 83():106394. PubMed ID: 32193102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibiting the NLRP3 inflammasome with MCC950 ameliorates retinal neovascularization and leakage by reversing the IL-1β/IL-18 activation pattern in an oxygen-induced ischemic retinopathy mouse model.
    Sui A; Chen X; Shen J; Demetriades AM; Yao Y; Yao Y; Zhu Y; Shen X; Xie B
    Cell Death Dis; 2020 Oct; 11(10):901. PubMed ID: 33093455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition.
    Coll RC; Hill JR; Day CJ; Zamoshnikova A; Boucher D; Massey NL; Chitty JL; Fraser JA; Jennings MP; Robertson AAB; Schroder K
    Nat Chem Biol; 2019 Jun; 15(6):556-559. PubMed ID: 31086327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition.
    Vande Walle L; Stowe IB; Šácha P; Lee BL; Demon D; Fossoul A; Van Hauwermeiren F; Saavedra PHV; Šimon P; Šubrt V; Kostka L; Stivala CE; Pham VC; Staben ST; Yamazoe S; Konvalinka J; Kayagaki N; Lamkanfi M
    PLoS Biol; 2019 Sep; 17(9):e3000354. PubMed ID: 31525186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases.
    Coll RC; Robertson AA; Chae JJ; Higgins SC; Muñoz-Planillo R; Inserra MC; Vetter I; Dungan LS; Monks BG; Stutz A; Croker DE; Butler MS; Haneklaus M; Sutton CE; Núñez G; Latz E; Kastner DL; Mills KH; Masters SL; Schroder K; Cooper MA; O'Neill LA
    Nat Med; 2015 Mar; 21(3):248-55. PubMed ID: 25686105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the NLRP3 Inflammasome With Inhibitor MCC950 Prevents Aortic Aneurysms and Dissections in Mice.
    Ren P; Wu D; Appel R; Zhang L; Zhang C; Luo W; Robertson AAB; Cooper MA; Coselli JS; Milewicz DM; Shen YH; LeMaire SA
    J Am Heart Assoc; 2020 Apr; 9(7):e014044. PubMed ID: 32223388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The NLRP3 inflammasome modulates glycolysis by increasing PFKFB3 in an IL-1β-dependent manner in macrophages.
    Finucane OM; Sugrue J; Rubio-Araiz A; Guillot-Sestier MV; Lynch MA
    Sci Rep; 2019 Mar; 9(1):4034. PubMed ID: 30858427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of NLRP3 inflammasome inhibition by MCC950 on LPS-induced pancreatic adenocarcinoma inflammation.
    Yaw ACK; Chan EWL; Yap JKY; Mai CW
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2219-2229. PubMed ID: 32507974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A selective NLRP3 inflammasome inhibitor attenuates behavioral deficits and neuroinflammation in a mouse model of Parkinson's disease.
    Huang S; Chen Z; Fan B; Chen Y; Zhou L; Jiang B; Long H; Zhong W; Li X; Li Y
    J Neuroimmunol; 2021 May; 354():577543. PubMed ID: 33714750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NLRP3 Inflammasome Regulates Development of Systemic Inflammatory Response and Compensatory Anti-Inflammatory Response Syndromes in Mice With Acute Pancreatitis.
    Sendler M; van den Brandt C; Glaubitz J; Wilden A; Golchert J; Weiss FU; Homuth G; De Freitas Chama LL; Mishra N; Mahajan UM; Bossaller L; Völker U; Bröker BM; Mayerle J; Lerch MM
    Gastroenterology; 2020 Jan; 158(1):253-269.e14. PubMed ID: 31593700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of NLRP3 inflammasome ameliorates podocyte damage by suppressing lipid accumulation in diabetic nephropathy.
    Wu M; Yang Z; Zhang C; Shi Y; Han W; Song S; Mu L; Du C; Shi Y
    Metabolism; 2021 May; 118():154748. PubMed ID: 33675822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage, and dysfunction in salt-sensitive hypertension.
    Krishnan SM; Ling YH; Huuskes BM; Ferens DM; Saini N; Chan CT; Diep H; Kett MM; Samuel CS; Kemp-Harper BK; Robertson AAB; Cooper MA; Peter K; Latz E; Mansell AS; Sobey CG; Drummond GR; Vinh A
    Cardiovasc Res; 2019 Mar; 115(4):776-787. PubMed ID: 30357309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.